COO,EOLS Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: ALGN SYK JNJ ISRG BSX ZBH MDT BAX HOLX STE

| Held by: VTI VOO VB VBR IVV SPY RSP XLV IWR VHT

Index	S&P 500	P/E	44.32	EPS (ttm)	1.87	Insider Own	0.68%	Shs Outstand	195.90M	Perf Week	2.63%
Market Cap	16.28B	Forward P/E	16.76	EPS next Y	4.96	Insider Trans	2.62%	Shs Float	194.64M	Perf Month	-0.22%
Enterprise Value	18.95B	PEG	1.69	EPS next Q	1.03	Inst Own	106.45%	Short Float	4.18%	Perf Quarter	17.43%
Income	374.90M	P/S	3.98	EPS this Y	9.73%	Inst Trans	2.78%	Short Ratio	3.06	Perf Half Y	14.25%
Sales	4.09B	P/B	1.97	EPS next Y	9.61%	ROA	3.03%	Short Interest	8.13M	Perf YTD	1.33%
Book/sh	42.06	P/C	147.16	EPS next 5Y	9.90%	ROE	4.59%	52W High	94.17 -11.81%	Perf Year	-11.13%
Cash/sh	0.56	P/FCF	37.53	EPS past 3/5Y	-1.15% 9.30%	ROIC	3.43%	52W Low	61.78 34.44%	Perf 3Y	-0.88%
Dividend Est.	-	EV/EBITDA	17.87	Sales past 3/5Y	7.35% 10.98%	Gross Margin	60.67%	Volatility	2.33% 2.17%	Perf 5Y	-13.71%
Dividend TTM	-	EV/Sales	4.63	EPS Y/Y TTM	-4.47%	Oper. Margin	16.69%	ATR (14)	1.88	Perf 10Y	147.41%
Dividend Ex-Date	Jul 26, 2023	Quick Ratio	1.13	Sales Y/Y TTM	5.06%	Profit Margin	9.16%	RSI (14)	57.61	Recom	2.14
Dividend Gr. 3/5Y	- -	Current Ratio	1.89	EPS Q/Q	-26.90%	SMA20	2.11%	Beta	1.03	Target Price	90.56
Payout	0.00%	Debt/Eq	0.34	Sales Q/Q	4.60%	SMA50	2.07%	Rel Volume	0.55	Prev Close	81.57
Employees	15000	LT Debt/Eq	0.33	Earnings	Mar 05 AMC	SMA200	11.08%	Avg Volume	2.66M	Price	83.05
IPO	Jan 21, 1983	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.30% 0.42%	Trades		Volume	1,472,558	Change	1.81%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-26	Reiterated	Needham	Buy	$100 → $99
Nov-13-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$72
Oct-13-25	Initiated	Barclays	Overweight	$85
Oct-01-25	Initiated	Goldman	Sell	$64
Aug-28-25	Downgrade	Citigroup	Buy → Neutral	$72
Jul-22-25	Upgrade	BNP Paribas Exane	Neutral → Outperform	$92
Jun-17-25	Upgrade	Needham	Hold → Buy	$94
May-30-25	Downgrade	JP Morgan	Overweight → Neutral	$76
Aug-29-24	Reiterated	Piper Sandler	Overweight	$115 → $120
Jul-16-24	Upgrade	Jefferies	Hold → Buy	$107 → $115
Mar-19-24	Upgrade	Redburn Atlantic	Neutral → Buy	$125
Mar-13-24	Upgrade	JP Morgan	Neutral → Overweight	$100 → $120
Feb-06-24	Resumed	KeyBanc Capital Markets	Sector Weight
Oct-30-23	Initiated	BofA Securities	Buy	$380
Oct-05-23	Downgrade	Redburn Atlantic	Overweight → Neutral	$390 → $343
May-30-23	Initiated	Morgan Stanley	Equal-Weight	$410
Dec-22-22	Initiated	Mizuho	Buy	$375
Nov-30-22	Upgrade	Robert W. Baird	Neutral → Outperform	$345 → $375
Oct-12-22	Downgrade	Jefferies	Buy → Hold	$400 → $295
Aug-29-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight

Show Previous Ratings

Today 01:34PM	BD Merges Biosciences & Diagnostics Business With Waters (Zacks)
Feb-10-26 09:23AM	The Cooper Companies (COO) Moved Higher as Multiple Tailwinds Align (Insider Monkey)
Feb-05-26 04:15PM	CooperCompanies Announces Release Date for First Quarter 2026 (GlobeNewswire)
Feb-04-26 05:20PM	Align Technology (ALGN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-03-26 01:17PM	Reasons to Add Cooper Companies Stock to Your Portfolio Now (Zacks)
12:10PM	Loading…
12:10PM	Will The Cooper Companies (COO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:05AM	Diamond Hill Large Cap Fund Purchased Cooper Companies (COO) Betting on the Resilient Contact Lens Industry (Insider Monkey)
Feb-02-26 11:57AM	BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics (Zacks)
Jan-29-26 11:38PM	1 Healthcare Stock to Own for Decades and 2 We Question (StockStory)
12:17PM	CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up (Zacks)
Jan-28-26 11:40AM	COO vs. WST: Which Stock Should Value Investors Buy Now? (Zacks)
Jan-27-26 12:19PM	Here's Why You Should Add Merit Medical Stock to Your Portfolio Now (Zacks)
09:45AM	Why The Cooper Companies (COO) is a Top Growth Stock for the Long-Term (Zacks)
Jan-26-26 09:40AM	Here's Why The Cooper Companies (COO) is a Strong Value Stock (Zacks)
Jan-23-26 01:50PM	WST Launches Synchrony S1 Prefillable Syringe at Pharmapack (Zacks)
07:57AM	Loading…
07:57AM	What You Need to Know Ahead of The Cooper Companies' Earnings Release (Barchart)
Jan-22-26 11:08AM	Here's Why You Should Retain Integer Holdings Stock in Your Portfolio (Zacks)
10:43AM	BD and Ypsomed Expand Partnership to Target Growing Biologics Market (Zacks)
Jan-21-26 11:43AM	BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System (Zacks)
Jan-14-26 12:50PM	Reasons to Add West Pharmaceutical Stock to Your Portfolio Now (Zacks)
Jan-13-26 11:16AM	Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial (Benzinga)
Jan-12-26 11:40AM	COO or WST: Which Is the Better Value Stock Right Now? (Zacks)
Jan-07-26 03:00PM	40 stocks likely to outperform in 2026: Boyar pres. explains (Yahoo Finance Video)
Jan-06-26 08:00AM	CooperVision to Launch MyDay MiSight 1 day Myopia Control Soft Contact Lenses (PR Newswire)
Jan-05-26 07:17AM	Hologic Trading Near 52-Week High: How Should You Play the Stock? (Zacks)
Jan-01-26 10:32PM	Medical Devices & Supplies - Diversified Stocks Q3 In Review: CooperCompanies (NASDAQ:COO) Vs Peers (StockStory)
Dec-31-25 07:36AM	What Makes The Cooper Companies (COO) an Investment Bet? (Insider Monkey)
Dec-30-25 02:04PM	Top Stock Reports for Berkshire Hathaway, AstraZeneca & Intel (Zacks)
07:33AM	Reasons to Add Cooper Companies Stock to Your Portfolio Now (Zacks)
Dec-29-25 04:15PM	CooperCompanies to Present at the J.P. Morgan Healthcare Conference (GlobeNewswire)
11:40AM	Loading…
Dec-26-25 11:40AM	COO vs. MMSI: Which Stock Is the Better Value Option? (Zacks)
Dec-23-25 08:00AM	CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors (GlobeNewswire)
Dec-22-25 12:12PM	BD and Penn Institute Ink Collaboration to Advance Immunotherapy (Zacks)
Dec-19-25 09:55AM	The Cooper Companies (COO)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Dec-16-25 11:05PM	3 Reasons to Sell COO and 1 Stock to Buy Instead (StockStory)
11:37AM	BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe (Zacks)
Dec-12-25 09:50AM	Why The Cooper Companies (COO) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-11-25 07:34AM	Is The Cooper Companies Stock Underperforming the Nasdaq? (Barchart)
12:31AM	5 Insightful Analyst Questions From CooperCompanies's Q3 Earnings Call (StockStory)
Dec-10-25 11:40AM	COO or MMSI: Which Is the Better Value Stock Right Now? (Zacks)
Dec-08-25 09:40AM	Why The Cooper Companies (COO) is a Top Value Stock for the Long-Term (Zacks)
09:15AM	The Cooper Companies (COO) International Revenue Performance Explored (Zacks)
Dec-05-25 11:11AM	CooperCompanies (COO) Stock Trades Up, Here Is Why (StockStory) +5.67%
11:02AM	Analyst Report: The Cooper Companies, Inc. (Morningstar Research)
09:11AM	COO Gains as Q4 Earnings & Sales Beat Estimates, MyDay Adoption Rises (Zacks)
07:36AM	Warner Bros. shares rise on Netflix deal news, Hewlett Packard Enterprise slumps on earnings and more early market movers (MarketWatch)
02:46AM	Stock Market Today: Dow, S&P 500 and Nasdaq point to gains as investors await Fed's preferred inflation gauge; bitcoin slips, silver surges (MarketWatch)
12:31AM	COO Q3 Deep Dive: Product Momentum and Strategic Review Shape Outlook (StockStory)
12:02AM	The Cooper Companies Inc (COO) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Dec-04-25 06:30PM	The Cooper Companies (COO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	The Cooper Companies (COO) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:45PM	CooperCompanies (NASDAQ:COO) Reports Q3 CY2025 In Line With Expectations, Stock Soars (StockStory)
04:20PM	CooperCompanies Announces New Chair of the Board and Strategic Review (GlobeNewswire)
04:15PM	CooperCompanies Announces Fourth Quarter and Full Year 2025 Results (GlobeNewswire)
Dec-03-25 05:15PM	HealthEquity (HQY) Tops Q3 Earnings and Revenue Estimates (Zacks)
12:45PM	Cooper Companies to Post Q4 Earnings: What's in Store for the Stock? (Zacks)
Dec-02-25 10:04PM	What To Expect From CooperCompanies's (COO) Q3 Earnings (StockStory)
Dec-01-25 09:15AM	Curious about The Cooper Companies (COO) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
06:11AM	1 Profitable Stock to Own for Decades and 2 We Find Risky (StockStory)
Nov-30-25 07:27AM	Stocks drift back towards record highs as the final month of 2025 gets underway: What to watch this week (Yahoo Finance)
07:27AM	Stocks drift back toward record highs as the final month of 2025 gets underway: What to watch this week (Yahoo Finance)
Nov-27-25 10:00AM	The Cooper Companies (COO) Earnings Expected to Grow: Should You Buy? (Zacks)
Nov-23-25 11:36PM	1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds (StockStory)
Nov-21-25 06:36PM	CooperCompanies, iRhythm, Baxter, Omnicell, and Neogen Shares Skyrocket, What You Need To Know (StockStory) +6.13%
Nov-19-25 06:38AM	Cooper Companies Stock: Analyst Estimates & Ratings (Barchart)
Nov-14-25 05:10PM	Jana Partners' Strategic Move: Significant Addition of The Cooper Companies Inc (GuruFocus.com)
Nov-13-25 05:20PM	Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
09:10AM	Here Are Thursdays Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More (24/7 Wall St.)
Nov-06-25 07:40AM	Becton Dickinson (BDX) Tops Q4 Earnings and Revenue Estimates (Zacks)
Nov-05-25 06:30PM	Conmed (CNMD) Tops Q3 Earnings and Revenue Estimates (Zacks)
Nov-04-25 04:15PM	CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025 (GlobeNewswire)
Nov-03-25 12:00PM	Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings? (Zacks)
Oct-31-25 10:23AM	4 Resilient Dental Supply Players Positioned to Withstand Tariff Risks (Zacks)
Oct-28-25 01:54AM	What to Expect From Cooper Companies Next Quarterly Earnings Report (Barchart)
Oct-21-25 09:24AM	Company News for Oct 21, 2025 (Zacks)
Oct-20-25 09:34AM	Stocks to Watch Monday: Amazon, Zions Bancorp, Kering (The Wall Street Journal)
08:21AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:41AM	Cooper Cos. Stock Rises as Report Says Activist Investor Takes Stake (Barrons.com)
07:25AM	Activist Jana Pushes Big Contact-Lens Combination of Cooper and Bausch + Lomb (The Wall Street Journal)
Oct-19-25 08:00PM	Activist Jana Takes Stake in Cooper, a Maker of Medical Devices (The Wall Street Journal)
Oct-16-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Oct-01-25 11:01AM	Goldman Sachs initiates ophthalmology coverage: Buy Glaukos, sell Cooper (Investing.com)
Sep-26-25 11:30AM	The Cooper Companies (COO) Up 3.6% Since Last Earnings Report: Can It Continue? (Zacks)
12:39AM	3 Healthcare Stocks That Fall Short (StockStory)
Sep-22-25 09:46AM	Reasons to Retain Cooper Companies Stock in Your Portfolio for Now (Zacks)
Sep-19-25 01:55AM	Is Cooper Companies Stock Underperforming the S&P 500? (Barchart)
Sep-18-25 11:42AM	Why CooperCompanies (COO) Stock Is Up Today (StockStory)
Sep-17-25 04:15PM	CooperCompanies Announces Expanded Share Repurchase Program (GlobeNewswire)
Sep-15-25 09:40AM	Here's Why The Cooper Companies (COO) is a Strong Value Stock (Zacks)
Sep-09-25 12:02AM	3 Reasons COO is Risky and 1 Stock to Buy Instead (StockStory)
Sep-03-25 01:31AM	5 Insightful Analyst Questions From CooperCompanies's Q2 Earnings Call (StockStory)
Sep-02-25 03:30PM	Why CooperCompanies (COO) Shares Are Falling Today (StockStory)
Sep-01-25 09:15AM	Interpreting The Cooper Companies (COO) International Revenue Trends (Zacks)
Aug-31-25 11:34PM	Medical Devices & Supplies - Diversified Stocks Q2 Recap: Benchmarking CooperCompanies (NASDAQ:COO) (StockStory)
Aug-29-25 09:47AM	COO Q3 Earnings Beat, 2025 Sales Outlook Lowered, Stock Down (Zacks)
09:40AM	Why The Cooper Companies (COO) is a Top Value Stock for the Long-Term (Zacks)
Aug-28-25 05:28PM	Why Cooper Companies Stock Sank by 13% Today (Motley Fool) -12.85%
04:25PM	These Stocks Moved the Most Today: Nvidia, Snowflake, Pure Storage, CrowdStrike, Hormel Foods, Cooper, HP, and More (Barrons.com)
04:05PM	Why CooperCompanies (COO) Shares Are Falling Today (StockStory)

The Cooper Cos, Inc. operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues. The Cooper Surgical segment focuses on the provision of advancement for the health of women, babies, and families through women's health and fertility products and services. The company was founded in 1958 and is headquartered in San Ramon, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jay Colleen	Director	Jan 12 '26	Option Exercise	39.40	7,064	278,322	36,585	Jan 14 04:05 PM
White Albert G III	President & CEO	Jan 08 '26	Option Exercise	0.00	18,340	0	254,491	Jan 12 04:24 PM
Warner Gerard H III	President, CooperVision, Inc.	Jan 08 '26	Option Exercise	0.00	11,518	0	29,837	Jan 12 04:24 PM
Sheffield Holly R	President, CSI	Jan 08 '26	Option Exercise	0.00	8,050	0	47,102	Jan 12 04:23 PM
McBride Daniel G	EVP & Chief Operating Officer	Jan 08 '26	Option Exercise	0.00	12,887	0	76,007	Jan 12 04:23 PM
Andrews Brian G	EVP, CFO & Treasurer	Jan 08 '26	Option Exercise	0.00	3,528	0	10,430	Jan 12 04:22 PM
Lucchese Cynthia L	Director	Dec 22 '25	Buy	84.06	1,784	149,963	9,445	Dec 23 04:08 PM
Rivas Maria	Director	Dec 18 '25	Buy	82.13	1,000	82,130	11,141	Dec 19 04:18 PM
Kurzius Lawrence Erik	Director	Dec 17 '25	Buy	82.50	2,000	165,000	7,777	Dec 17 05:06 PM
Sheffield Holly R	President, CSI	Dec 16 '25	Buy	80.75	1,230	99,322	39,052	Dec 16 06:36 PM
White Albert G III	President & CEO	Dec 16 '25	Buy	80.80	10,000	808,000	236,151	Dec 16 06:36 PM
Kurzius Lawrence Erik	Director	Sep 29 '25	Buy	68.39	2,000	136,780	5,777	Sep 29 08:36 PM
White Albert G III	President & CEO	Sep 05 '25	Buy	68.39	10,000	683,900	226,151	Sep 05 05:10 PM
Warner Gerard H III	President, CooperVision, Inc.	Sep 05 '25	Buy	69.23	1,450	100,384	18,319	Sep 05 04:07 PM
McBride Daniel G	EVP & Chief Operating Officer	Sep 02 '25	Buy	65.04	3,000	195,120	63,120	Sep 02 05:17 PM
Andrews Brian G	EVP, CFO & Treasurer	Sep 02 '25	Buy	65.68	1,525	100,162	22,191	Sep 02 05:16 PM
KOZY WILLIAM A	Director	Apr 01 '25	Option Exercise	0.00	2,857	0	31,149	Apr 03 04:09 PM
WEISS ROBERT S	Director	Apr 01 '25	Option Exercise	0.00	2,993	0	288,945	Apr 03 04:09 PM
Rivas Maria	Director	Apr 01 '25	Option Exercise	0.00	2,721	0	2,721	Apr 03 04:08 PM
MADDEN TERESA S	Director	Apr 01 '25	Option Exercise	0.00	2,721	0	12,357	Apr 03 04:08 PM
Lucchese Cynthia L	Director	Apr 01 '25	Option Exercise	0.00	2,721	0	7,661	Apr 03 04:07 PM
Kurzius Lawrence Erik	Director	Apr 01 '25	Option Exercise	0.00	2,721	0	3,777	Apr 03 04:07 PM
Jay Colleen	Director	Apr 01 '25	Option Exercise	0.00	2,721	0	29,521	Apr 03 04:06 PM
Ricupati Agostino	SVP & CAO	Apr 01 '25	Option Exercise	0.00	2,076	0	9,044	Apr 03 04:06 PM

Peers: ABBV LLY PFE AMGN BMY RVNC MRK TEVA PRGO PRPH

| Held by: VTI IWM VXF XPH IWO VTWO SCHA VHT IHE IWC

Index	RUT	P/E	-	EPS (ttm)	-0.91	Insider Own	23.39%	Shs Outstand	64.77M	Perf Week	-6.32%
Market Cap	278.73M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	0.08%	Shs Float	49.66M	Perf Month	-25.48%
Enterprise Value	390.10M	PEG	-	EPS next Q	0.03	Inst Own	80.33%	Short Float	14.88%	Perf Quarter	-39.01%
Income	-58.56M	P/S	0.98	EPS this Y	-79.67%	Inst Trans	-10.36%	Short Ratio	6.00	Perf Half Y	-32.81%
Sales	285.82M	P/B	-	EPS next Y	62.38%	ROA	-26.11%	Short Interest	7.39M	Perf YTD	-35.34%
Book/sh	-0.44	P/C	6.40	EPS next 5Y	-	ROE	-18729.61%	52W High	17.12 -74.88%	Perf Year	-68.77%
Cash/sh	0.67	P/FCF	-	EPS past 3/5Y	4.74% 23.91%	ROIC	-47.36%	52W Low	4.20 2.38%	Perf 3Y	-52.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	38.76% 50.12%	Gross Margin	64.34%	Volatility	6.85% 6.37%	Perf 5Y	-38.92%
Dividend TTM	-	EV/Sales	1.36	EPS Y/Y TTM	0.17%	Oper. Margin	-14.35%	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.53	Sales Y/Y TTM	15.10%	Profit Margin	-20.49%	RSI (14)	32.22	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	2.02	EPS Q/Q	19.93%	SMA20	-9.66%	Beta	1.02	Target Price	14.67
Payout	-	Debt/Eq	-	Sales Q/Q	12.90%	SMA50	-27.01%	Rel Volume	0.74	Prev Close	4.45
Employees	332	LT Debt/Eq	-	Earnings	Nov 05 AMC	SMA200	-43.33%	Avg Volume	1.23M	Price	4.30
IPO	Feb 08, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.85% 2.36%	Trades		Volume	907,536	Change	-3.37%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Downgrade	Needham	Buy → Hold
Apr-17-25	Initiated	BTIG Research	Buy	$21
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $16
Jun-23-22	Initiated	Needham	Buy	$18
May-12-22	Upgrade	Barclays	Underweight → Equal Weight	$8 → $10
Jan-20-22	Upgrade	Truist	Hold → Buy	$11
May-06-21	Upgrade	Mizuho	Neutral → Buy	$15
Apr-08-21	Reiterated	H.C. Wainwright	Buy	$20 → $22
Feb-24-21	Downgrade	Truist	Buy → Hold	$12
Jul-07-20	Downgrade	Mizuho	Buy → Neutral	$8 → $3
Feb-06-20	Resumed	Mizuho	Buy
Nov-26-19	Initiated	SVB Leerink	Outperform	$25
Sep-05-19	Resumed	Mizuho	Buy	$30
Jun-28-19	Initiated	Wells Fargo	Market Perform	$16
Jun-11-19	Initiated	Barclays	Underweight	$13
Mar-20-19	Initiated	SunTrust	Buy	$30
Feb-14-19	Initiated	H.C. Wainwright	Buy	$37
Jan-29-19	Initiated	Stifel	Buy	$27

Show Previous Ratings

Feb-09-26 02:13PM	Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating (Insider Monkey) -5.78%
Feb-04-26 07:40AM	Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates (Zacks)
Jan-09-26 08:30AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue (Business Wire)
Dec-15-25 11:10PM	Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics (Insider Monkey)
Nov-14-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:04AM	Loading…
Nov-06-25 12:04AM	Evolus Inc (EOLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com) +5.43%
Nov-05-25 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +6.24%
04:05PM	Evolus Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-30-25 10:00AM	Earnings Preview: Prestige Consumer Healthcare (PBH) Q2 Earnings Expected to Decline (Zacks)
Oct-29-25 10:00AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-28-25 08:00AM	Evolus to Participate in 2025 Stifel Healthcare Conference (Business Wire)
Oct-22-25 08:00AM	Evolus to Report Third Quarter Financial Results on November 5, 2025 (Business Wire)
Oct-10-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-22-25 09:03AM	Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse Filler Launch (PR Newswire)
Sep-12-25 05:30PM	Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.79%
08:30AM	Loading…
Sep-08-25 08:30AM	Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer (Business Wire)
Aug-25-25 08:00AM	Evolus Announces Positive Data From Pivotal Trial for Evolysse Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp (Business Wire)
Aug-20-25 08:00AM	Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse Sculpt Injectable Hyaluronic Acid Gel Product (Business Wire)
Aug-08-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-05-25 06:30PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -28.51%
04:05PM	Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Jul-31-25 10:00AM	Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:05AM	Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau as a Top Performer Among Leading Neurotoxins (Business Wire)
Jul-29-25 10:00AM	Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline (Zacks)
Jul-22-25 08:05AM	Evolus to Report Second Quarter Financial Results on August 5, 2025 (Business Wire)
Jul-11-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-25 08:00AM	Evolus Expands Global Footprint with Introduction of Nuceiva (botulinum toxin type A) in France (Business Wire)
Jun-13-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-10-25 08:00AM	Evolysse Recognized in 2025 Shape Skin Awards (Business Wire)
May-27-25 04:15PM	Evolus Announces Departure of its Chief Financial Officer (Business Wire) -5.20%
08:00AM	Loading…
May-22-25 08:00AM	Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels (Business Wire)
May-16-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-13-25 09:51AM	Evolus, Inc. (EOLS): A Bull Case Theory (Insider Monkey)
May-08-25 09:47AM	Q1 2025 Evolus Inc Earnings Call (Thomson Reuters StreetEvents) -14.20%
03:28AM	Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com)
May-07-25 07:14PM	Evolus projects $345M-$355M revenue for 2025 with new product launches (Seeking Alpha)
07:13PM	Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:55PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports First Quarter 2025 Results (Business Wire)
May-05-25 04:05PM	Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility (Business Wire)
May-01-25 07:30AM	SNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-23-25 08:00AM	Evolus to Report First Quarter Financial Results on May 7, 2025 (Business Wire) +7.36%
Apr-22-25 07:10PM	Evolus: Two-Product Aesthetics Company With A Competitive Edge (Seeking Alpha)
Apr-18-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-16-25 08:00AM	Evolus Announces Commercial Launch of Evolysse (Business Wire)
Apr-15-25 08:00AM	Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse Injectable Hyaluronic Acid Gels (Business Wire)
Mar-25-25 08:00AM	Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference (Business Wire)
Mar-21-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-10-25 04:53PM	Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas (Motley Fool) -6.63%
Mar-05-25 07:13AM	Q4 2024 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com)
Mar-04-25 05:25PM	Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates (Zacks)
04:05PM	Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance (Business Wire)
Mar-02-25 06:08PM	Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-27-25 08:00AM	Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences (Business Wire)
Feb-20-25 08:00AM	Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit (Business Wire)
Feb-18-25 08:00AM	Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 (Business Wire)
Feb-14-25 08:53AM	Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Feb-13-25 01:30PM	Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels (Business Wire) +5.47%
Feb-07-25 07:09PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-22-25 07:46AM	Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? (Zacks)
Jan-21-25 04:04PM	Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere Here's Why (Investor's Business Daily) +28.26%
08:00AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Companys Guidance (Business Wire)
Jan-17-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 09:55AM	Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-14-24 09:35AM	Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) (Zacks)
Nov-07-24 06:00AM	Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges (GuruFocus.com) -14.99%
Nov-06-24 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports Third Quarter 2024 Results (Business Wire)
Nov-01-24 08:00AM	Evolus to Participate in Stifel 2024 Healthcare Conference (Business Wire)
Oct-31-24 02:02PM	Evolus Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation (Business Wire)
Oct-30-24 10:01AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-29-24 08:00AM	Evolus Rewards Patient Loyalty Program Surpasses 1 Million Enrolled Consumers (Business Wire)
Oct-23-24 08:00AM	Evolus to Report Third Quarter Financial Results on November 6, 2024 (Business Wire)
Oct-11-24 10:53PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 03:36PM	Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Sep-27-24 09:00PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 08:00AM	Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 (Business Wire)
Aug-09-24 04:30PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:39AM	Evolus, Inc. (EOLS): Is It One of Caligan Partners Top Holdings Now? (Insider Monkey)
Aug-01-24 04:00PM	Evolus, A Medical Aesthetics Player, Becomes Profitable Two Quarters Early (Investor's Business Daily) +13.04%
Jul-31-24 09:56PM	EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
06:45PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance (Business Wire)
08:00AM	Evolus to Hold Investor Day on September 12, 2024 (Business Wire)
Jul-30-24 08:00AM	Evolus Expands Global Footprint with Introduction of Nuceiva (botulinum toxin type A) in Australia (Business Wire)
Jul-25-24 08:00AM	Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-23-24 07:03AM	Evoluss frown line treatment Jeuveau could threaten Botox revenues (Pharmaceutical Technology)
Jul-17-24 08:00AM	Evolus to Report Second Quarter Financial Results on July 31, 2024 (Business Wire)
Jul-01-24 08:00AM	Evolus Announces Appointment of Albert G. White III to Board of Directors (Business Wire)
Jun-24-24 08:00AM	Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse Dermal Filler Products (Business Wire)
Jun-12-24 08:00AM	Evolus Broadens International Presence with Launch of Nuceiva (botulinum toxin type A) in Spain (Business Wire)
Jun-07-24 05:00PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.73%
May-28-24 01:00AM	The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space (WWD)
May-21-24 10:57AM	Evolus (EOLS) Releases Favorable Dermal Fillers Study Data (Zacks)
May-20-24 08:30AM	Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse Dermal Filler Products at 2024 SCALE Meeting (Business Wire)
May-16-24 02:54AM	Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS) (GuruFocus.com)
02:54AM	Director Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS) (GuruFocus.com)

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOATAZEDI DAVID	See Remarks	Dec 22 '25	Sale	7.15	10,539	75,361	354,388	Dec 29 06:42 PM
Avelar Rui	See Remarks	Dec 22 '25	Sale	7.15	2,261	16,168	356,821	Dec 29 06:42 PM
Yamagishi-Dressler Tomoko	Chief Marketing Officer	Aug 22 '25	Sale	7.51	5,722	42,972	89,949	Aug 26 06:26 PM
Stewart Brady	Director	Aug 15 '25	Buy	6.82	30,000	204,486	88,629	Aug 18 04:28 PM
MOATAZEDI DAVID	See Remarks	Jun 13 '25	Sale	10.05	111,323	1,119,141	381,509	Jun 16 04:42 PM
MOATAZEDI DAVID	See Remarks	Jun 16 '25	Sale	9.89	16,582	164,054	364,927	Jun 16 04:42 PM
DAVID MOATAZEDI	Officer	Jun 16 '25	Proposed Sale	9.89	16,582	164,052		Jun 16 04:03 PM
DAVID MOATAZEDI	Officer	Jun 13 '25	Proposed Sale	10.05	111,323	1,119,141		Jun 13 05:23 PM
White Albert G III	Director	Jun 09 '25	Buy	9.45	20,000	189,000	50,378	Jun 10 05:04 PM
Avelar Rui	See Remarks	May 12 '25	Sale	9.87	3,385	33,397	359,082	May 14 07:27 PM
Beaver Sandra	Chief Financial Officer	May 13 '25	Sale	10.02	6,494	65,070	167,089	May 14 07:27 PM
MOATAZEDI DAVID	See Remarks	May 12 '25	Sale	9.87	15,787	155,756	492,832	May 14 07:27 PM
MOATAZEDI DAVID	See Remarks	Mar 27 '25	Sale	12.40	6,251	77,512	508,619	Mar 28 06:59 PM
Avelar Rui	See Remarks	Mar 18 '25	Sale	13.26	27,904	369,868	362,467	Mar 20 06:27 PM
Beaver Sandra	Chief Financial Officer	Mar 18 '25	Sale	13.26	8,996	119,243	173,583	Mar 20 06:27 PM
Yamagishi-Dressler Tomoko	Chief Marketing Officer	Mar 18 '25	Sale	13.26	4,536	60,125	95,671	Mar 20 06:27 PM
MOATAZEDI DAVID	See Remarks	Mar 18 '25	Sale	13.26	103,376	1,370,249	514,870	Mar 20 06:27 PM
Parschauer Karah Herdman	Director	Mar 12 '25	Sale	12.99	12,888	167,465	32,183	Mar 14 05:59 PM
Parschauer Karah Herdman	Director	Mar 12 '25	Proposed Sale	12.99	12,888	167,465		Mar 12 05:55 PM

COO

Cooper Companies, Inc

EOLS

Evolus Inc

Upgrade your FINVIZ experience